Newsroom

Dendrogenix today announced that the first patient has been dosed in the Phase IIa clinical trial evaluating DX243 in patients with age-related hearing loss, also known as presbycusis.

This milestone represents a major step forward in the development of DX243, a potentially first-in-class pharmacological treatment design to target key biological mechanisms involved in age-related hearing loss, a condition for which no approved drug treatment addressing the underlying disease biology is currently available.

A major unmet medical need

Age-related hearing loss, or presbycusis, is the leading cause of hearing impairment in adults, affecting hundreds of millions of people worldwide. Beyond the progressive loss of hearing thresholds, presbycusis is characterized ...

Dendrogenix reports the publication of new preclinical results highlighting the ability of DX243 to protect the most vulnerable auditory circuits from age-related degeneration.

Published in Frontiers in Pharmacology (2026), this study from the Tübingen Hearing Research Centre (University of Tübingen, Germany) demonstrates that a 14-day daily treatment with DX243 preserves the functional integrity of critical auditory synapses involved in temporal sound processing and speech understanding in noisy environments—capabilities that decline early in Age-Related Hearing Loss (presbycusis).

Protective effects persist for up to 6 weeks after treatment cessation, supporting a durable disease-modifying effect on cochlear synaptopathy rather than short-term symptomatic relief.

Unlike ...